Mer­ck KGaA looks to boost drug R&D al­liances as the CFO crunch­es the num­bers on de­vel­op­ment costs

Most every­body at the high end of the drug R&D busi­ness has more tri­al work on the ta­ble than they can af­ford to com­plete alone. And that’s where the right de­vel­op­ment part­ner can make a big dif­fer­ence.

For Mer­ck KGaA, Pfiz­er has been shoul­der­ing much of the load to ad­vance their PD-L1 check­point Baven­cio, now in mul­ti­ple stud­ies for var­i­ous can­cers as it con­tin­ues to chase a crowd­ed field of play­ers. And the same ap­proach could work else­where.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.